The drug promotes lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis.

Once considered a niche concern, it is now a growing global epidemic affecting more than one in four adults worldwide.

Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

Once considered a niche concern, it is now a growing global epidemic affecting more than one in four adults worldwide.

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

By Dr. Jaisingh Rajput Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting individuals ...

Belly fat is more than a cosmetic concern—it can signal fatty liver disease. Learn how early diagnosis and lifestyle changes ...

Non-alcoholic fatty liver disease is predicted to become the leading indicator for liver transplant necessity within the ...

Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

A new study found that dapagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, improved key liver conditions ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

Objective Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum of non-alcoholic fatty liver disease (NAFLD). Design ...